Overexpression of prothymosin-α in glioma is associated with tumor aggressiveness and poor prognosis.

Abstract

Prothymosin-α (PTMA), a nuclear protein, is strikingly associated with unfavorable clinical outcomes in many cancers. However, no information about its clinical relevance in glioma was available. Therefore in the present study, we evaluated the prognostic utility of this protein in a cohort of 81 glioma patients. The PTMA expression was assessed by immunohistochemical analysis, quantitative PCR, and Western blotting. Furthermore, the association of PTMA with clinicopathological features and molecular alterations were assessed in the patient cohort and validated in multiomics datasets, The Cancer Genome Atlas (TCGA; n=667) and Chinese Glioma Genome Atlas (CGGA; n=1013). We observed an increase in PTMA expression with increasing histological grades of this malignancy. PTMA immunostaining also displayed a strong positive association with the MIB-1 index. Univariate analysis revealed a superior prognostic value of PTMA to predict overall survival (OS) as compared with the routinely used markers (p53, isocitrate dehydrogenase (IDH) 1 (IDH1), α-thalassemia/intellectual disability syndrome X-linked (ATRX), and Ki-67). Interestingly, in Cox regression analysis it emerged as an independent predictor of OS (hazard ratio (HR) = 13.71, 95% CI = 5.96-31.52, P<0.0001). Thus, our results demonstrate the potential prognostic utility of PTMA in glioma which may prove useful in the management of this deadly malignancy.

• Authors: Anurag Kumar, Vikas Kumar, Mohit Arora, Manish Kumar, Prajwal Ammalli, Bhaskar Thakur, Jitender Prasad, Sarita Kumari, Mehar Chand Sharma, Shashank Sharad Kale, Shyam S Chauhan
• Journal: Bioscience reports (Biosci Rep) Vol. 42 Issue 4 (04 29 2022) ISSN: 1573-4935 [Electronic] England
• PMID: 35297481 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 The Author(s).

Chemical References

• Biomarkers, Tumor

Topics

• Biomarkers, Tumor (genetics)
• Brain Neoplasms (metabolism)
• Cohort Studies
• Glioma (pathology)
• Humans
• Proportional Hazards Models